NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » ACTIVITIES ENGAGED IN: TCM  1  2  3  4  5  » 
found files: 87
NCCSED »06/03/2007 [Industry news]
Frontier links with NCCSED (CRO) in China

US based Frontier Biosciences has signed agreement with National Chengdu Centre for Safety Evaluation of Drugs - a full service pre-clinical CRO regarded as one of the best in China - established by West China Hospital of the Sichuan University...   more»


Simcere Pharmaceutical Group »19/04/2007 [Finance]
Simcere Pharmaceutical Group Announces Pricing of Initial Public Offering on NYSE

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market, announced today that its initial public offering of 15,625,000 American Depositary Shares (ADSs), each representing two ordinary shares, was priced at an initial public offering price of $14.50 per ADS. The ADSs will begin trading on the New York Stock Exchange on April 20, 2007 under the symbol ''SCR.''...   more»


Simcere Pharmaceutical Group »03/06/2007 [Industry news]
Simcere Pharmaceutical Group is looking to build its future on research

Flush with cash from its US IPO, Simcere Pharmaceutical Group is looking to build its future on research. Late last month, Simcere weighed in with the largest IPO on the New York Stock Exchange for an Asian pharmaceutical company, raising 261 mln usd. Now it plans to put some of that money to work. 'We need to consider both the long-term and the short-term,' said Jinsheng Ren, chairman and CEO. 'Pharmaceutical technology can really set companies apart in China and that is why we say R & D is our focus.' "THIS HIGHLY RESPECTED COMPANY COULD BE A GOOD PARTNER FOR HLS"...   more»


China Sky One Medical,Inc. »05/07/2007 [Company watch]
China Sky One Medical Passes Recent SFDA Inspection

China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that its facilities and products passed a surprise inspection by China State Food and Drug Administration (SFDA) on June 28, 2007. Government officials and industry professionals working for the SFDA inspected the Company\\\\\\\'s production process, including the quality of raw materials, final packaging, consumer instructions, as well as stock-keeping methods...   more»


VENTURE PHARM SERVICE--VPScro »27/07/2007 [Company watch]
Raising HK$ 97 million-- VPS-CRO---- A Chinese Leader in Preclinical & Clinical Service Is Ready To Run

On 27 July 2007, the Company and a Swiss financial corporation, entered into the Note Purchase Agreement in respect of the issue of the Convertible Notes in the principal amount of CHF 15 million (approximately HK$ 97.2 million) due 2012....   more»


Hutchison China MediTech Limited(“Chi-Med”) »20/08/2007 [Company watch]
Hutchison China Medipharma agrees collaboration deal with Eli Lilly

Hutchison China Meditech, the China-based pharmaceutical company, said its unit Hutchison MediPharma has agreed a research collaboration with US pharmaceutical company Eli Lilly (NYSE:LLY) to co-develop oncology and anti-inflammatory medicines. Hutchison said it will receive milestone payments of 20-29 mln usd, depending on the clinical candidate, along with an upfront fee, annual research and development support costs and also potential royalties. Under the terms of the agreement, Hutchison will take responsibility for initial research and development, while Eli Lilly will offer technological advice and clinical trial expertise as the project advances. The research will be carried out in China to 'expedite the drug discovery process and reduce overall costs', Hutchison said....   more»


Lotus Pharmaceuticals »21/08/2007 [Company watch]
Lotus Pharmaceuticals, Reports $21 Million in Revenues and $4.1 Million in Net Profits in Quarterly Filing

Lotus Pharmaceuticals, Inc. released its second quarter results, with revenues topping $21 million, net profits of $4.1 million, and net assets of $17 million. r. Adam Wasserman, Lotus Chief Financial Officer, reported: ``Total revenues for the six months ended June 30, 2007 were $21,095,000 as compared to total revenues of $16,047,000 for the six months ended June 30, 2006, an increase of $5,048,000 or approximately 31.5%. Lotus' working capital position increased $4,783,000 to $13,429,000 at June 30, 2007 from $8,646,000 at December 31, 2006.'' Dr. Shaohua Tan, Genesis Director in Beijing, observed: ``Lotus seems to go from strength-to-strength. Just six weeks ago, Gold Horse International joined Lotus as a graduate from our private-to-public program. We are hopeful that a third Chinese partner company, prominent in environmental technologies, will join these alumni as a new U.S. public company before the end of Genesis' current fiscal year.''...   more»


Simcere Pharmaceutical Group »04/10/2007
Simcere Pharmaceutical Group, a manufacturer of anti-cancer medication Endu, said it agreed to buy a 51% stake in Boda Pharmaceutical Co., Ltd

This company is off on the acquisition trail !...   more»


China Sky One Medical,Inc. »13/11/2007 [Company watch]
China Sky One Medical Reports Third Quarter 2007 Financial Results

3Q07 Revenue Up 148% to $16.8 Million ---- 3Q07 Net Income Up 195% to $5.4 Million HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced financial results for the three month and nine month periods ending September 30, 2007....   more»


Simcere Pharmaceutical Group »26/11/2007 [Company watch]
Simcere Acquires Nanjing Tung Chit

Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, announced today that it has acquired 100% of Master Luck Corporation Limited, which holds 85.7% of Nanjing Tung Chit Pharmaceutical Co., Ltd. ("Tung Chit"), for a total cash consideration of RMB32.6 million (US$4.4 million). Tung Chit is a fast-growing manufacturer and supplier of anti-cancer drugs in China. Its leading product is a nedaplatin injection, trademarked as Jiebaisu, a first-to-market platinum based chemotherapeutic drug approved for the treatment of a wide range of solid tumors, including head-and-neck cancer, small cell and non-small cell lung cancer and esophageal cancer. Since its launch, Jiebaisu has been used by a number of major Chinese hospitals, specializing in cancer treatment, in many provinces across China. According to the China Hospital Drug Information, Jiebaisu's share of the nedaplatin market in China was over 80 percent in 2006. Being a new generation, broad spectrum platinum based chemotherapeutic drug, nedaplatin is expected to have significant growth potential in China....   more»


Lotus Pharmaceuticals »17/01/2008 [Company watch]
Lotus Pharmaceuticals Inc. Retains CCG Elite

Lotus Pharmaceuticals, Inc. ("Lotus" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign...   more»


Simcere Pharmaceutical Group »20/03/2008 [Company watch]
Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Sales appointments

Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announces the appointment of Mr. Mark Chen, Pei-Chi as Vice President of Marketing and the promotion of Baoxing Zha and Dasheng Sun as the Vice Presidents of Hospital Sales and Retail Sales respectively....   more»


Hutchison China MediTech Limited(“Chi-Med”) »27/03/2008 [Company watch]
Hutchison China losses increase

Hutchison China Meditech (AIM: HCM) reported higher 2007 revenues, but also said its net loss increased. Revenues were up 29% to $65.1 million, while the loss jumped from $10 million to $17.2 million. Revenues for its line of TCM products were higher, and that division of its business was profitable. Chi-Med, as the company is popularly known, blamed the loss on higher research expenses and a one-time charge of $5.1 million for discontinuing its Nao Ling Tong product line....   more»


VENTURE PHARM SERVICE--VPScro »02/04/2008 [Company watch]
Commonwealth Forms Joint Venture with Venturepharm for Outsourcing Services

Commonwealth Biotechnologies, Inc. and Venturepharm Laboratories Ltd have formed a China-based joint venture that will provide a continuous spectrum of outsourcing services. The move came after Venturepharm bought a 39% stake in CBI. The 2.15 million block of shares, which had previously belonged to PharmAust Ltd., has a market value of $5.85 million. The China JV will be known as Venturepharm Asia. It will be the “shop front” for Venturepharm’s CRO services. The JV is unusual in that both contributing organizations are already publicly traded, but it follows a recent pattern of CROs in the west and the east forming alliances to provide a greater number of services in a geographically diversified manner. CBI will contribute early stage drug discovery technologies, business development, marketing and quality assurance services to the JV. Venturepharm will provide contract manufacturing and clinical trial services. Dr. Paul D'Sylva, CEO of CBI, noted that 60% of the $34 billion that life sciences companies spend on outsourcing went to contract manufacturing. Clinical research was the recipient of 33% of the total and 7% went to custom chemical synthesis. For CBI, the JV allows it to offer contract manufacturing and clinical trial management to clients who have used Commonwealth for its custom synthesis and other services. CBI now operates the following units: • CBI Services (Richmond, VA), a discovery phase contract research organization; • Fairfax Identity Laboratories, a DNA reference business; • Mimotopes Pty, Ltd (Melbourne, Australia), a peptide and discovery chemistry business; Exelgen, Ltd (Bude, UK), a medicinal and synthetic discovery chemistry business; • Venturepharm Asia (Beijing, China), process scale-up, formulation development, cGMP manufacturing and clinical trial management. CBI’s headquarters are in San Diego, while Venturepharm is based in Beijing. Venturepharm Laboratories Limited provides a large complement of drug discovery and development services that take new drugs from "idea to patients." These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial management, product registration, marketing & sales to pharmaceutical and biotech companies in China and overseas....   more»


China Sky One Medical,Inc. »02/04/2008 [Company watch]
China Sky One Medical, Inc. announced its 2007 revenues

China Sky One Medical, Inc. announced its 2007 revenues climbed 148% to $49.3 million. The company’s net income came in at $15.3 million, which equals $1.15 per share fully diluted and a profit margin of 31%. The company makes and markets traditional Chinese Medicines, most of which are for external use. It also produces diagnostic products....   more»


Simcere Pharmaceutical Group »22/04/2008 [Company watch]
Simcere acquires 70% in Wuhu Zhong Ren Pharma

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, has signed a definitive agreement to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical for a total cash consideration of RMB 64.82 million ($9.26 million). This transaction is consistent with Simcere's strategy to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio. Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants. Its key product SinoFuan (fluorouracil implant), is proven to effectively inhibit the growth of tumors, and is the only sustained release anti-tumor implant approved by the State Food and Drug Administration (SFDA). SinoFuan is commonly used to treat cancers of the digestive tract and is a favored choice for use during surgery. No similar product exists on the Chinese market today. The distribution of SinoFuan through Simcere's established marketing channels will enhance Simcere's offerings in the anti-cancer drug market, benefit cancer patients across China and create greater value for Simcere shareholders....   more»


VENTURE PHARM SERVICE--VPScro »18/04/2008 [Company watch]
Commonwealth Biotechnologies, Inc. (CBTE) and Venturepharm Laboratories Ltd have formed a China-based joint venture

Commonwealth Biotechnologies, Inc. and Venturepharm Laboratories Ltd have formed a China-based joint venture that will provide a continuous spectrum of outsourcing services. The move came after Venturepharm bought a 39% stake in CBI. The 2.15 million block of shares, which had previously belonged to PharmAust Ltd., has a market value of $5.85 million. The China JV will be known as Venturepharm Asia. It will be the “shop front” for Venturepharm’s CRO services. The JV is unusual in that both contributing organizations are already publicly traded, but it follows a recent pattern of CROs in the west and the east forming alliances to provide a greater number of services in a geographically diversified manner. CBI will contribute early stage drug discovery technologies, business development, marketing and quality assurance services to the JV. Venturepharm will provide contract manufacturing and clinical trial services. Dr. Paul D'Sylva, CEO of CBI, noted that 60% of the $34 billion that life sciences companies spend on outsourcing went to contract manufacturing. Clinical research was the recipient of 33% of the total and 7% went to custom chemical synthesis. For CBI, the JV allows it to offer contract manufacturing and clinical trial management to clients who have used Commonwealth for its custom synthesis and other services. CBI now operates the following units: • CBI Services (Richmond, VA), a discovery phase contract research organization; • Fairfax Identity Laboratories, a DNA reference business; • Mimotopes Pty, Ltd (Melbourne, Australia), a peptide and discovery chemistry business; Exelgen, Ltd (Bude, UK), a medicinal and synthetic discovery chemistry business; • Venturepharm Asia (Beijing, China), process scale-up, formulation development, cGMP manufacturing and clinical trial management. CBI’s headquarters are in San Diego, while Venturepharm is based in Beijing. Venturepharm Laboratories Limited provides a large complement of drug discovery and development services that take new drugs from "idea to patients." These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial management, product registration, marketing & sales to pharmaceutical and biotech companies in China and overseas....   more»


Lotus Pharmaceuticals »22/04/2008 [Company watch]
Lotus Actively Increasing Its Share of China’s Pharma Market

In The Odyssey, the lotus-eaters were a tribe of people who were addicted to the lotus plant, a plant that left them in an opium-like state of blissful apathy. It does not seem like an appropriate name for Lotus Pharmaceuticals (LTUS.OB), because the company is anything but apathetic. Instead, it seems intent upon increasing its share of China’s pharmaceutical market. Lotus Pharmaceuticals reported it made a profit of $11.2 million on revenues of $56.9 million in 2007. For the year, profits almost tripled, while revenues increased 57%. Without one-time items, net income would have been $8.5 million. Even at the lower figure, net earnings were 19 cents per fully diluted share, a jump of 34% over 2006. On December 31, 2007, Lotus had $4.6 million in cash and $24.7 million in working capital. Already in 2008, Lotus has floated a $4.6 million offering of Series A Convertible Redeemable Preferred Stock. The company used $2.6 million to repay its 14% secured convertible notes, and the rest will be added to working capital....   more»


Simcere Pharmaceutical Group »18/05/2008 [Company watch]
Simcere Pharmaceutical Group Announces SFDA Approval Of First-To-Market Generic Biapenem Injection A

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, recently announced that it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market a first-to-market generic Biapenem injection under the brand name Anxin. Anxin is the first Biapenem injection approved for sale in China, and will be used for the treatment of serious infections. Biapenem is a member of the fast-growing carbenicillin family, like Tienam from Merck & Co. Inc. and Mepem from Sumitomo Pharmaceuticals Co. Ltd., with a potential market in China of RMB1.6 billion. This family of drug has seen an approximate 30% year over year growth rate in China over the last three years. As is the case with first-to- market branded generics in China, Anxin will enjoy an exclusive four-year market monitoring period, during which the SFDA will not accept further requests for approval of pharmaceuticals with the same chemical structure, dosage form and indication, that have not yet entered into clinical trial. Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere, commented, "The approval of Anxin, a Simcere developed Biapenem injection, strengthens the company's antibiotic product portfolio in line with our strategy to focus on first-to-market generic and innovative drugs. More importantly, it provides a new and effective treatment for patients with serious infections who have experienced resistance to other antibiotics."...   more»


China Sky One Medical,Inc. »23/05/2008 [Company watch]
China Sky One Receives Approval for Two New Drugs

China Sky One Medical, Inc. (CSKI.OB) was granted SFDA approval for two new drugs: Oxymetazoline Hydrochloride Nasal Drops and Taurine Eye Drops. Oxymetazoline Hydrochloride Nasal Drops are indicated for the treatment of acute and chronic rhinitis, sinusitis and allergic rhinitis. Taurine Eye Drops are approved for the treatment of acute and chronic conjunctivitis. Both rhinitis and conjunctivitis are common in China, especially in colder regions. With the new products, China Sky One now has a portfolio of 98 drugs overall and 49 products that are administered externally. In addition, the company will have submitted a total of 37 additional new drugs to the SFDA by the end of 2008. Because of its distribution network, which China Sky One says is more extensive than the companies that make competitors to the new products, China Sky One expects its new products to quickly capture at least 10% of their respective markets. The company did not make specific revenue predictions. Recently, China Sky One reported first quarter revenues 140% higher than the year-earlier quarter....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.